United Kingdom· GB-APID-39134711000001102
Enerzair Breezhaler 114micrograms/dose / 46micrograms/dose / 136micrograms/dose inhalation powder capsules with device
A medicinal product containing mometasone + glycopyrronium bromide + indacaterol, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Mometasone + Glycopyrronium bromide + Indacaterol
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07613421042295
- gtin07613421042288
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mometasone + glycopyrronium bromide + indacaterol in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaENERZAIR BREEZHALERNovartis Europharm Limited, Dublin
- FinlandEnerzair BreezhalerNovartis Europharm Limited
- IrelandEnerzair Breezhaler 114 micrograms/46 micrograms/136 micrograms inhalation powder, hard capsulesNovartis Europharm Limited
- SwedenEnerzair Breezhaler 114 mikrogram/46 mikrogram/136 mikrogram Inhalationspulver, hård kapselNovartis Europharm Limited
- NorwayEnerzair BreezhalerNovartis Europharm Limited (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enerzair Breezhaler, Zimbus Breezhaler
- Liechtenstein · Enerzair Breezhaler, Zimbus Breezhaler
- Norway · Enerzair Breezhaler, Zimbus Breezhaler
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/138fd117-6167-4e0a-8a9d-2b8c40707597 GET /v1/drugs/138fd117-6167-4e0a-8a9d-2b8c40707597?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "39134711000001102",
"desc": "Enerzair Breezhaler 114micrograms/dose / 46micrograms/dose / 136micrograms/dose inhalation powder capsules with device (Novartis Pharmaceuticals UK Ltd)",
"form": "Inhalation powder",
"vpid": "39134511000001107",
"source": "dmd",
"vtm_id": "39133711000001104",
"strength": "136 microgram",
"substance": "Mometasone + Glycopyrronium bromide + Indacaterol",
"ingredient": "Mometasone furoate",
"supplier_code": "2920101000001102"
}See everything about mometasone + glycopyrronium bromide + indacaterol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.